Kerri-Ann Millar
Director of Finance/CFO presso CUE BIOPHARMA, INC.
Patrimonio netto: 29 412 $ in data 31/03/2024
Profilo
Kerri-Ann Millar is currently the Chief Financial Officer at Cue Biopharma, Inc. since 2020.
Prior to this, she worked as a Controller at Flexion Therapeutics, Inc. from 2014 to 2017.
She completed her undergraduate degree at Boston University in 1992.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
CUE BIOPHARMA, INC.
0.03% | 06/03/2024 | 15 562 ( 0.03% ) | 29 412 $ | 31/03/2024 |
Posizioni attive di Kerri-Ann Millar
| Società | Posizione | Inizio |
|---|---|---|
| CUE BIOPHARMA, INC. | Director of Finance/CFO | 30/04/2018 |
Precedenti posizioni note di Kerri-Ann Millar
| Società | Posizione | Fine |
|---|---|---|
| FLEXION THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 01/09/2017 |
Formazione di Kerri-Ann Millar
| Boston University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
| Cue Biopharma, Inc. |
- Borsa valori
- Insiders
- Kerri-Ann Millar
